SEC Company Response from CERENOME, (CNSY) — Jun 5, 2026
CERENOME, INC.
Date: June 5, 2026 · CIK: 0001095981 · Accession: 0001193125-26-258709
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296411
Letter
Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 filed on June 2, 2026 File No. 333-296411 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc. hereby requests for acceleration of the effective date of the above-referenced registration statement, as amended, so that it becomes effective as of 5:00 p.m. Eastern Time on Friday, June 5, 2026, or as soon thereafter as possible. [Signature Page to Follow]
June 5, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Very truly yours,
Plus Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 5, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-3 filed on June 2, 2026 File No. 333-296411 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc. hereby requests for acceleration of the effective date of the above-referenced registration statement, as amended, so that it becomes effective as of 5:00 p.m. Eastern Time on Friday, June 5, 2026, or as soon thereafter as possible. [Signature Page to Follow] Very truly yours, Plus Therapeutics, Inc. By: /s/ Andrew Sims Name: Andrew Sims Title: Chief Financial Officer cc: Charles E. Chambers, Sullivan & Worcester LLP [Signature Page to Acceleration Request]